[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100335082":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":90,"collaborators":10,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":94,"sex":100,"minAge":101,"maxAge":10,"enrollmentInfo":102,"targetDuration":10,"studyType":105,"phases":10,"briefSummary":106,"conditions":107,"keywords":10,"overallStatus":60,"whyStopped":10,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nīmes","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with rheumatoid polyarthritis",null,[12],"Other: Questionnaire",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Questionnaire","Patients are asked to complete several questionnaires",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Cécile Gaujoux Viala, MD","CONTACT","04 66 68 31 20","cecile.gaujoux.viala@chu-nimes.fr",[25,44,58,75],{"facility":26,"status":27,"city":28,"state":10,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"CHU Bordeaux","NOT_YET_RECRUITING","Bordeaux","33000","France","FR",{"type":33,"coordinates":34},"Point",[35,36],-0.58046,44.84124,{"lat":36,"lon":35},[39,42],{"name":40,"role":21,"phone":10,"phoneExt":10,"email":41},"Christophe Richez, MD","christophe.richez@chu-bordeaux.fr",{"name":40,"role":43,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":45,"status":27,"city":46,"state":10,"zip":47,"country":30,"countryCode":31,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"CHRU Montpellier","Montpellier","34295",{"type":33,"coordinates":49},[50,51],3.87635,43.61093,{"lat":51,"lon":50},[54,57],{"name":55,"role":21,"phone":10,"phoneExt":10,"email":56},"Jacques Morel, MD","j-morel@chu-montpellier.fr",{"name":55,"role":43,"phone":10,"phoneExt":10,"email":10},{"facility":59,"status":60,"city":61,"state":10,"zip":62,"country":30,"countryCode":31,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"CHU Nimes","RECRUITING","Nîmes","30029",{"type":33,"coordinates":64},[65,66],4.35788,43.83665,{"lat":66,"lon":65},[69,73],{"name":70,"role":21,"phone":71,"phoneExt":10,"email":72},"Anissa Megzari","04.66.68.42.36","drc@chu-nimes.fr",{"name":74,"role":43,"phone":10,"phoneExt":10,"email":10},"Cécile Gaujoux Viala",{"facility":76,"status":27,"city":77,"state":10,"zip":78,"country":30,"countryCode":31,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"CHU Toulouse","Toulouse","31300",{"type":33,"coordinates":80},[81,82],1.44367,43.60426,{"lat":82,"lon":81},[85,88],{"name":86,"role":21,"phone":10,"phoneExt":10,"email":87},"Arnaud Constantin","arnaud.constantin@univ-tlse3.fr",{"name":89,"role":43,"phone":10,"phoneExt":10,"email":10},"Arnaud Constantin, MD",{"type":91,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100335082","validation-of-the-french-version-of-the-cqr-compliance-questionnaire-rheumatology-100335082",false,"NCT03642795","Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology)","Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology): Specific Tool for Evaluation of Observance of Rheumatology Treatment","CQR-F","Inclusion Criteria:\n\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n* The patient is at least 18 years old\n* The patient has rheumatoid polyarthritis as defined by the ACR-EULAR 2010 criteria, treated orally or subcutaneously with MTX for at least 3 months with a stable (unchanged) dosage for at least 1 month, and a stable (unchanged) route of administration for at least 1 month. And no planned change in Methotrexate intake at least until the second study visit. Other treatments at the same time are authorized\n\nExclusion Criteria:\n\n* The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study\n* The subject refuses to sign the consent\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* The subject has a contraindication to taking methotrexate (including a patient with a desire to become pregnant).","ALL","18 Years",{"count":103,"type":104},150,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to develop a French language version of the Compliance-Questionnaire-Rheumatology for use in French and Francophone rheumatology services",[108],"Rheumatoid Polyarthritis","2025-11-25",{"date":111,"type":112},"2025-12-03","ACTUAL",{"date":114,"type":112},"2022-06-23",{"date":116,"type":104},"2029-03",{"name":5,"class":6},4]